Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266961 | 0.64 | HKDC1 (0.30) | HKDC1 | |
| SCHEMBL4611579 | 0.62 | — | — | |
| SCHEMBL9599429 | 0.61 | — | — | |
| SCHEMBL4731704 | 0.60 | — | — | |
| SCHEMBL13370334 | 0.60 | ADRA1A (0.31) | — | |
| SCHEMBL11387218 | 0.57 | — | — | |
| SCHEMBL871965 | 0.57 | CDC25A (0.36) | HKDC1 | |
| SCHEMBL9578416 | 0.57 | — | — | |
| SCHEMBL6136964 | 0.57 | — | — | |
| SCHEMBL11812594 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971898-A1 | SUBSTITUTED ISOQUINOLINES AS ULTRA SHORT ACTING NEUROMUSCULAR BLOCKERS | GLAXO GROUP LIMITED (GB) | 2000-01-19 | — | — | EP | claimed |
| WO-1998042675-A1 | SUBSTITUTED ISOQUINOLINES AS ULTRA SHORT ACTING NEUROMUSCULAR BLOCKERS | GLAXO GROUP LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| EP-0365397-A2 | Beta-D-phenyl thioxylosides, method for their preparation and their use in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1990-04-25 | — | — | EP | claimed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-107903256-B | A kind of 2,4- di-amino-pyrimidine and its application containing substituted thiazole | 南方医科大学 | 2019-11-15 | — | — | CN | disclosed |
| EP-3426661-A1 | 4BETA-AMIDOTRIAZOLE LINKED PODOPHYLLOTOXIN DERIVATIVES AS POTENTIAL ANTICANCER AGENTS | Council of Scientific & Industrial Research (IN) | 2019-01-16 | — | — | EP | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9771372-B2 | Compounds useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2017-09-26 | — | — | US | disclosed |
| WO-2017154026-A1 | 4BETA-AMIDOTRIAZOLE LINKED PODOPHYLLOTOXIN DERIVATIVES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-14 | — | — | WO | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | disclosed |
| US-6288109-B1 | Pyranones, method for the production and use thereof | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-0574510-A4 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | INNOVATIVE TECH CENTER (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0574510-A1 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-12-22 | — | — | EP | disclosed |
| EP-0365397-A2 | Beta-D-phenyl thioxylosides, method for their preparation and their use in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | HKDC1 3939/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | HKDC1 3918/4885 |
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | HKDC1 3193/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | HKDC1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.